{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:17:33Z","timestamp":1760300253795,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017R1C1B5017516"],"award-info":[{"award-number":["NRF-2017R1C1B5017516"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prostate-specific antigen (PSA) kinetics predicts survival in castration-resistant prostate cancer (CRPC); however, the influence of prior treatment on this relationship is unclear. Patients with CRPC were stratified according to time to PSA nadir and time to CRPC progression to investigate their prognostic significance on prostate cancer-specific survival (PCSS) and whether PSA kinetics may serve as prognosticators regardless of prior local treatment. This multicenter retrospective study included 295 patients diagnosed with CRPC between September 2009 and November 2017. PSA kinetics during androgen-deprivation therapy (ADT) including %PSA decline, PSA nadir level, time to PSA nadir, and time to CRPC progression was investigated. Subgroup analysis was performed according to the prior history of local curative treatment. Patients who did not receive prior local treatment with \u22656 months to PSA nadir and &lt;12 months to CRPC, showed lower PCSS rates than those with &lt;6 months to PSA nadir (23.3% vs. 45.3%; <jats:italic>p<\/jats:italic>\u2009=\u20090.031) and \u226512 months to CRPC (20.0% vs. 47.8%; <jats:italic>p<\/jats:italic>\u2009=\u20090.001). In patients who had received local treatment, PSA kinetic parameters did not influence PCSS. Our results indicate that time to PSA nadir and time to CRPC progression are prognosticators of PCSS in patients with CRPC who did not previously receive curative local treatment.<\/jats:p>","DOI":"10.1038\/s41598-019-48424-6","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T10:02:31Z","timestamp":1565863351000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Yoon Soo","family":"Hah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9984-1138","authenticated-orcid":false,"given":"Jong Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8588-7584","authenticated-orcid":false,"given":"Koon Ho","family":"Rha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Joon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9817-3660","authenticated-orcid":false,"given":"Byung Ha","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyo Chul","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"48424_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1464-410X.2010.09878.x","volume":"108","author":"ES Antonarakis","year":"2011","unstructured":"Antonarakis, E. S. et al. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int. 108, 378\u2013385 (2011).","journal-title":"BJU Int."},{"key":"48424_CR2","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1200\/JCO.2003.01.075","volume":"21","author":"AV D\u2019amico","year":"2003","unstructured":"D\u2019amico, A. V. et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 21, 2163\u20132172 (2003).","journal-title":"J Clin Oncol."},{"key":"48424_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1200\/JCO.2005.11.148","volume":"23","author":"H Brenner","year":"2005","unstructured":"Brenner, H. & Arndt, V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol. 23, 441\u2013447 (2005).","journal-title":"J Clin Oncol."},{"key":"48424_CR4","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.1992.03480160073037","volume":"267","author":"HB Carter","year":"1992","unstructured":"Carter, H. B. et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 267, 2215\u20132220 (1992).","journal-title":"JAMA."},{"key":"48424_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa032975","volume":"351","author":"AV D\u2019Amico","year":"2004","unstructured":"D\u2019Amico, A. V., Chen, M. H., Roehl, K. A. & Catalona, W. J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 351, 125\u2013135 (2004).","journal-title":"N Engl J Med."},{"key":"48424_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.294.4.440","volume":"294","author":"AV D\u2019Amico","year":"2005","unstructured":"D\u2019Amico, A. V., Renshaw, A. A., Sussman, B. & Chen, M. H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 294, 440\u2013447 (2005).","journal-title":"JAMA."},{"key":"48424_CR7","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.1200\/JCO.2005.01.2336","volume":"23","author":"DA Patel","year":"2005","unstructured":"Patel, D. A. et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 23, 6157\u20136162 (2005).","journal-title":"J Clin Oncol."},{"key":"48424_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/sj.pcan.4500424","volume":"3","author":"S Egawa","year":"2000","unstructured":"Egawa, S. et al. Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis. 3, 269\u2013274 (2000).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"48424_CR9","doi-asserted-by":"publisher","first-page":"6992","DOI":"10.1200\/JCO.2005.01.2906","volume":"23","author":"P Zhou","year":"2005","unstructured":"Zhou, P. et al. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 23, 6992\u20136998 (2005).","journal-title":"J Clin Oncol."},{"key":"48424_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland, S. J. et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 294, 433\u2013439 (2005).","journal-title":"JAMA."},{"key":"48424_CR11","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/cncr.22550","volume":"109","author":"AV D\u2019Amico","year":"2007","unstructured":"D\u2019Amico, A. V., McLeod, D. G., Carroll, P. R., Cullen, J. & Chen, M. H. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer. 109, 1290\u20131295 (2007).","journal-title":"Cancer."},{"key":"48424_CR12","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","volume":"24","author":"M Hussain","year":"2006","unstructured":"Hussain, M. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 24, 3984\u20133990 (2006).","journal-title":"J Clin Oncol."},{"key":"48424_CR13","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/pros.21334","volume":"71","author":"SP Huang","year":"2011","unstructured":"Huang, S. P. et al. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate. 71, 1189\u20131197 (2011).","journal-title":"Prostate."},{"key":"48424_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2490-14-33","volume":"14","author":"A Tomioka","year":"2014","unstructured":"Tomioka, A. et al. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer. BMC Urol. 14, 33 (2014).","journal-title":"BMC Urol."},{"key":"48424_CR15","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/cncr.1990.66.s5.1025","volume":"66","author":"EH Cooper","year":"1990","unstructured":"Cooper, E. H. et al. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer. 66, 1025\u20131028 (1990).","journal-title":"Cancer."},{"key":"48424_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/cncr.24064","volume":"115","author":"TK Choueiri","year":"2009","unstructured":"Choueiri, T. K. et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 115, 981\u2013987 (2009).","journal-title":"Cancer."},{"key":"48424_CR17","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","volume":"17","author":"GJ Bubley","year":"1999","unstructured":"Bubley, G. J. et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 17, 3461\u20133467 (1999).","journal-title":"J Clin Oncol."},{"key":"48424_CR18","unstructured":"Mottet, N. et al. EAU-ESTRO-ESURSIOG Guidelines on Prostate Cancer, European Association of Urology (2018)."},{"key":"48424_CR19","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0022-5347(05)66452-X","volume":"165","author":"CL Amling","year":"2001","unstructured":"Amling, C. L., Bergstralh, E. J., Blute, M. L., Slezak, J. M. & Zincke, H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 165, 1146\u20131151 (2001).","journal-title":"J Urol."},{"key":"48424_CR20","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.juro.2015.12.075","volume":"195","author":"A Toussi","year":"2016","unstructured":"Toussi, A. et al. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? J Urol. 195, 1754\u20131759 (2016).","journal-title":"J Urol."},{"key":"48424_CR21","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0022-5347(17)39757-4","volume":"144","author":"Y Arai","year":"1990","unstructured":"Arai, Y., Yoshiki, T. & Yoshida, O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol. 144, 1415\u20131419 (1990).","journal-title":"J Urol."},{"key":"48424_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/pcan.2011.14","volume":"14","author":"T Sasaki","year":"2011","unstructured":"Sasaki, T., Onishi, T. & Hoshina, A. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis. 14, 248\u2013252 (2011).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"48424_CR23","doi-asserted-by":"publisher","first-page":"203.e1","DOI":"10.1016\/j.urolonc.2015.01.017","volume":"33","author":"M Kim","year":"2015","unstructured":"Kim, M. et al. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer. Urol Oncol. 33, 203.e1\u20139 (2015).","journal-title":"Urol Oncol."},{"key":"48424_CR24","unstructured":"Carroll, P. et al. PSA testing for the pretreatment staging and posttreatment management of prostate cancer, https:\/\/www.auanet.org\/guidelines\/prostate-specific-antigen-(psa)-best-practice-statement (2013)."},{"key":"48424_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","volume":"177","author":"MS Cookson","year":"2007","unstructured":"Cookson, M. S. et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 177, 540\u2013545 (2007).","journal-title":"J Urol."},{"key":"48424_CR26","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach, M. 3rd et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in the men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 65, 965\u2013974 (2006).","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"48424_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45, 228\u2013247 (2009).","journal-title":"Eur J Cancer."},{"key":"48424_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/bimj.200710415","volume":"50","author":"MD Ruopp","year":"2008","unstructured":"Ruopp, M. D., Perkins, N. J., Whitcomb, B. W. & Schisterman, E. F. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom J. 50, 419\u2013430 (2008).","journal-title":"Biom J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48424-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48424-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48424-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:40:14Z","timestamp":1671280814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48424-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48424"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48424-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2019,8,15]]},"assertion":[{"value":"29 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11899"}}